NCT00527475 - Ranibizumab and Reduced Fluence PDT for AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Macular Degeneration

Interventions

DRUG

ranibizumab

0.5 mg. given as an intraocular injection

DRUG

verteporfin

Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.

Trial Locations (3)

Associated Retinal Consultants, Ann Arbor

Texas Retina Associates, Arlington

California Retina Consultants & Research Foundation, Santa Barbara